EMERYVILLE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that members of its management team will participate in fireside chats at two upcoming investor conferences: the Stifel 2021 Virtual Healthcare Conference and Guggenheim Virtual 3rd Annual Neuro/Immunology Conference.
| Guggenheim Virtual 3rd Annual Neuro/Immunology Conference Fireside Chat Details | |
| Date: | Monday, November 15, 2021 |
| Time: | 2:20 PM Eastern Time |
| Stifel 2021 Virtual Healthcare Conference Fireside Chat Details | |
| Date: | Tuesday, November 16, 2021 |
| Time: | 1:20 PM Eastern Time |
The fireside chats will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.
About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs: one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix also plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
CONTACTS:
Zogenix
corpcomms@zogenix.com
Investors
Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com
Media
Trish McCall, Porter Novelli
+1 (805) 390-3279 | trish.mccall@porternovelli.com
